case of overactive bladder. Phosphodiesterase type 5 inhibitors can be used in male erectile dysfunction and vaginal dilators in case of vaginal stenosis. Perineal pain can be observed. Neurological mechanism is the main mechanism and can be confirmed by means of electrophysiological testing. This neuropathic pain can be managed by various treatments (drugs, TENS, ...).


CO05-007–EN
Resource teams for pediatric palliative care and rehabilitation teams: Proximity, partnerships
C. Remy
ESPPéRA, IHOP, 1, place Joseph-Renault, 69 373 Lyon cedex 08, France

Keywords: Pediatric oncology; Supporting care; Rehabilitation; Network competence

The 4th measure of ministerial plan 2008–2012 relative to palliative care has enabled the creation or the development of regional resources teams in charge of pediatric palliative care.

In Rhone-Alpes, ESPPéRA (pediatric palliative team for supporting care, resource and accompaniment) was created January 1st 2011 to communicate about palliative approach and train health professionals in hospitals, medico-social institutions or private practices.

Pediatric palliative cares were initially developed by pediatric oncologists for children suffering from cancer; however, most children suffering from a pathology “limiting or threatening life” present more broadly a disability at some point in time in their care. At that point in time, a PMR team (physical medicine and rehabilitation) or medico-social team (such as accompaniment services, SESSAD, IME, CEM) provides care for them.

These caregivers are mainly trained for re-education and rehabilitation approach, which is similar to a palliative approach, as it relies on a care project which takes into consideration the patient deficiencies and incapacities, and is integrated to a life project without a cure outlook.

Yet, SSR or medico-social teams face difficulties when life is threatened at short or mid term: difficulties in identifying a palliative situation, in adapting the care project, in applying different techniques (such as palliative chemotherapy) or in handling the end of life symptoms. More generally, these teams may not feel comfortable or even legitimate at this moment of the child’s life.

I will first identify the different clinical situations that can lead a disabled child to begin palliative care, and I will then develop the specificities and complementarities between cultures and practices of rehabilitation teams and SPP resource teams. I will also consider how these teams could cross train each other.


Posters

Version française

P053–FR
Paraplegie après injection intrathécale de Méthotrexate
T. Nguyen, A. Palacio, F. Beuret-Blanquart
CRMPR les Herbiers, MPR, rééducation neurologique, 111, rue Herbeuse, 76230 Bois-Guillaume, France

Mots clés : Chimothérapie intrathécale ; Méthotrexate ; Cytarabine ; Paraplegie

Introduction.— Nous rapportons un cas de lymphome du manteau compliqué d’une paraplégie après injection intrathécale de Méthotrexate.

Observation.— Une femme de 53 ans, caucasienne, se présente en novembre 2009 pour cervical polyadénopathies. A node biopsy is performed, diagnosing mantle cell lymphoma. Chemotherapy according to the protocol LYMA (Rituximab maintenance regimen) was begun in December 2009. On January 20 2010, the second cure was delivered. The next day, a lumbar puncture including Methotrexate, Aracynite and Hydrocortisone was made. Eight days later, the patient develops flask paraplegia of motor and sensory level Th9 with urinary retention. The electromyography (EMG) brought to light a pluriradicular impingement. The magnetic resonance imaging (MRI) eliminated cord compression, and found an oedema of the terminal cone and the low dorsal marrow without abnormal contrast uptake. The infectious and autoimmune etiologic assessment was negative; the lumbar puncture was normal. The diagnosis of secondary myelitis due to the intrathecal injection of Methotrexate was retained. No improvement was noticed after bolus of corticoids. Thirteen months later, a follow-up MRI revealed medullary atrophy before the terminal cone. Since, the patient recovered partially but paraparesis persists with important sensory disorders; she can walk short distances with 2 crutches.

Discussion.— Neurotoxicity of intrathecal injections of Methotrexate is a rare complication; not enough cases have been well documented in the literature [1,2]. It can take several forms: meningeal irritation, epilepsy, encephalopathy, paraplegia even quadriplegia. The pathological mechanism is still unknown; several factors were incriminated: diluant, conservateur, fluide de liqueur céphalo-rachidien, carence locale dans les folates...L’évolution est variable : récupération partielle ou complète. Contrairement à ce qui est décrit dans la littérature, notre patiente a développé sa paraplegie dès la 1ère injection.

Références


Version anglaise

P053–EN
Paraplegia after intrathecal injection of Methotrexate
T. Nguyen, A. Palacio, F. Beuret-Blanquart
CRMPR les Herbiers, MPR, rééducation neurologique, 111, rue Herbeuse, 76230 Bois-Guillaume, France

Keywords: Intrathecal chemotherapy; Methotrexate; Cytarabine; Paraplegia

Introduction.— We report a case of mantle cell lymphoma complicated with paraplegia after intrathecal injection of Methotrexate.

Case report.— A 53-year-old Caucasian woman consulted in November 2009 for cervical polyadenopathies. A node biopsy is performed, diagnosing mantle cell lymphoma. Chemotherapy according to the protocol LYMA (Rituximab maintenance regimen) was begun in December 2009. On January 20 2010, the second cure was delivered. The next day, a lumbar puncture including Methotrexate, Aracynite and Hydrocortisone was made. Eight days later, the patient develops flask paraplegia of motor and sensory level Th9 with urinary retention. The electromyography (EMG) brought to light a pluriradicular impingement. The magnetic resonance imaging (MRI) eliminated cord compression, and found an oedema of the terminal cone and the low dorsal marrow without abnormal contrast uptake. The infectious and autoimmune etiologic assessment was negative; the lumbar puncture was normal. The diagnosis of secondary myelitis due to the intrathecal injection of Methotrexate was retained. No improvement was noticed after bolus of corticoids. Thirteen months later, a follow-up MRI revealed medullary atrophy before the terminal cone. Since, the patient recovered partially but paraparesis persists with important sensory disorders; she can walk short distances with 2 crutches.

Discussion.— Neurotoxicity of intrathecal injections of Methotrexate is a rare complication; not enough cases have been well documented in the literature [1,2]. It can take several forms: meningeal irritation, epilepsy, encephalopathy, paraplegia even quadriplegia. The pathological mechanism is still unknown; several factors were incriminated: diluant, preservatives, leakage of cerebrospinal fluid, local folate deficiency... The evolution is variable: partial or complete recovery. Contrary to what is described in the literature, our patient developed the paraplegia after the first injection.

© 2018 Elsevier Masson SAS. All rights reserved. - Document downloaded on 06/12/2018 It is forbidden and illegal to distribute this document.